Gland B2B Business Model and Growth Strategy slide image

Gland B2B Business Model and Growth Strategy

24 Consistent Regulatory Compliance Track Record Highlights H No warning letters from USFDA (whether as a result of facility inspection or otherwise) since inception of each facility All facilities Certified GMP compliant by USFDA, and certain facilities by MHRA (UK), ANVISA (Brazil), AGES (Austria), TGA (Australia) and BGV Hamburg (Germany) WHO GMP certifications from the Drugs Control Administration (Governments of Telangana and Andhra Pradesh, India) (DCA) Focus on Quality Control ISO certifications as of March 31, 2021 (1) eiie 1,191 fulltime employees in Quality Control and Quality Assurance (2) 30.07% of the workforce in Quality Control and Quality Assurance (2) 35+ audits on average per year, including customer audit and regulatory agency audit Quality Standards throughout the business units Quality Improvement Laboratory Information Management System software for quality control at all manufacturing locations and facilities Corporate Quality Establishment Corporate reporting structure for identifying and developing standard operating procedures Quality Audits Conduct internal audits across all facilities on a quarterly basis Note: (1) 3 ISO certifications as of March 31, 2021 for quality management, environment management and occupational health and safety management systems applicable to design, development and production of pharmaceuticals and contract manufacture of small volume parenterals. (2) As of March 31, 2021 GLAND
View entire presentation